Targeting RNA offers an opportunity to explore a new universe of therapeutics, but many small molecule drug candidates suffer from poor target selection and non-specific binding. MAGNA™ provides powerful insights to support target validation, hit-to-lead selection and lead optimization, accelerating RNA-targeted drug discovery.

In this webinar, Gordon Hamilton, President & CEO, will talk about how MAGNA™, an exciting new technology from Depixus based on magnetic force spectroscopy, can be used to:

• Measure the dynamics of drug binding to RNA structures
• Enable improved hit-to-lead selection through scalable, real time analysis
• Study different small molecule-RNA target interactions, using recent data